EBOS has announced a series of executive and board changes, including the appointment of Andrew McLean as chief executive officer of medical technology, the proposed transition of Matt Muscio to a non-executive director role, and the retirement of Peter Williams as a board director.
McLean, who has over 25 years of experience in the medical device and pharmaceutical industries, will assume his new role on Aug 5 2024.
Muscio will continue as CEO of medical technology until Dec 31 2024, and it is intended for him to be appointed as a non-executive director from Jan 1 2025, subject to a resolution at the 2024 annual meeting.
Williams, an independent director, will retire from the board with effect from the 2024 annual meeting.
See more
